From Research to Reality: Investing in HIV Prevention Research in a Challenging LandscapeThis is the ninth annual report on HIV prevention research funding prepared by the HIV Vaccines & Microbicides Resource Tracking Working Group (RTWG), led by AVAC, in partnership with the International AIDS Vaccine Initiative and UNAIDS. For the one-page overview of the report, see the Research to Reality Summary. Report graphics and presentations are available at www.hivresourcetracking.org.
The report provides detailed information on funding for the following prevention options—preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention, voluntary medical male circumcision and prevention of vertical transmission. In addition to funding information for R&D on the options above, the report also provides an update on investment in HIV cure, therapeutic vaccine and female condom research.
Top-line findings include:
- In 2012 funders reported investing a total of US$1.31 billion in research and development (R&D) for HIV prevention—a six percent increase over 2011 funding levels.
- A significant portion of the increase from 2011 to 2012 is due to improved reporting by several donors. The actual increase is moderate—an essential flatlining of funding.
- The United States remained the largest public sector funder of HIV prevention research, spending a total of US$925 million in 2012—70 percent of the total investment in HIV prevention R&D. The report authors point out the need for a broader funding base to support ongoing R&D.
- In 2012, there were 99,931 participants in HIV prevention research trials, primarily based in sites with high HIV burden in South Africa, Uganda and the US. Two-thirds of volunteers were in sub-Saharan Africa.
Visit the Working Group's website at www.hivresourcetracking.org to download From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape and to view additional Working Group reports, as well as graphics and PowerPoint slides.
For older versions of the report, visit here.